
- /
- Supported exchanges
- / US
- / CPRX.NASDAQ
Catalyst Pharmaceuticals Inc (CPRX NASDAQ) stock market data APIs
Catalyst Pharmaceuticals Inc Financial Data Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 535 M
- EBITDA: 269 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.5267
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News

Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run?
Have you been paying attention to shares of Catalyst Pharmaceutical (CPRX)? Shares have been on the move with the stock up 8.4% over the past month. The stock hit a new 52-week high of $26.58 in the p...


Kymera Therapeutics Stock Earns 92 RS Rating
Kymera Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 92. IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (be...

Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 11.4% in that time frame, outperforming the S&P 500. Will the recent positive tren...

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell d...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.